Our analysis demonstrates that unselective implementation of ERAS protocol can be safe in a low volume unit and realize its advantage by a marked decrease in operation time, shortened LOS and with more patients securely discharge on POD1 without an increase in complications.
Since the concept of a multimodal approach to control postoperative pathophysiology and improve recovery was first introduced in 1997 [16], relevant protocols have evolved. The rationale is to hasten convalescence by reducing perioperative stress. From then onwards, guidelines have been established regarding recommendations for integral ERAS components in bariatric field [14]. Recently, several systemic reviews and meta-analyses have demonstrated the superiority of enhanced recovery protocols in terms of carrying out more efficient surgical procedures, lessening the length of hospitalization and effectively reducing overall morbidities compared with standard care [8, 17, 18]. That being said, to generally implement the ERAS regimen remains questionable since this approach is not without risks [9, 19]. For instance, Rebibo et al. reported a cohort with a 40% increase in the readmission rate (from 4–5.6%; p < 0.01) [20]. Others observed an increase in the ER visit rate as a result of shortening the target LOS [21]. Using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program data set, Inaba et al. found a significantly higher morbidity (3.76% vs. 1.54%) and mortality rate (0.94% vs. 0.05%) when comparing same-day discharge to POD1 discharge after RYGB [22]. In another review from a large prospective database, Morton et al. discovered that an LOS of ≤ 1 day was associated with a significantly increased risk of 30-day mortality (OR 2.02) and a trend toward an increased risk of serious complications for RYGB patients [23]. In fact, the reasons to suggest ERAS be implemented under the setting of specialized high-volume centers reside in that mastered surgical technique beforehand is frequently deemed a prerequisite to conduct these projects safely [9]. For example, McCarty et al. proposed that 84% of patients can be discharged within 23 hours postoperatively with a readmission rate as low as 1.7% for 2000 consecutive RYGB patients [24]. Similarly, based on a single high-volume center, Jacobsen et al. published an ERAS cohort of 2000 consecutive RYGB cases with a significantly shortened hospital stay (from 3 days to 2 days), an early complication rate as low as 2.8% and a readmission rate of only 1.9% [25]. In this regard, it seems reckless to conduct ERAS in a non-accredited low volume unit with fewer than 50 perennial cases. By looking at our two-year results before ERAS inception with mean operative time plateaued at 147 min, LOS stabilized around 3.3 days and no conversions or mortality reported; we believe a safety standard had been reached despite there were no objective criteria to gauge readiness.
Unlike our study background, a vast accumulating experience can usually be found when referring to preceding research that has been conducted with low case numbers. Hahl et al. analyzed data from 318 out of 514 patients who underwent RYGB during a 4-year period with excellent results showing a mean LOS of only 1.3 days and 83% of patients discharged on POD1 [26]. Notably, their accumulative experience at that time was already far more than five hundred cases. Similar to our study, Awad et al. introduce a series of 226 cases that comprised various bariatric procedures. With a low 30-day complication rate of only 4.4% and a readmission rate of 2.7% [12]; however, this particular study were conducted at a regional high-volume tertiary referral center, wherein they already had a vast prior experience of more than 2000 RYGB procedures. Therefore, whether these superior outcomes result from specific ERAS programs or merely reflect clinician proficiency remains unclear. Some other studies were notably undertaken via independent patient-selection or procedure-selection process. Such as Sasse et al. presented a 38 RYGB case series with a 100% POD1 discharge rate and a low 30-day complication rate of only 2.6% [27]. However, their study group represented fewer than 3% of their total RYGB cases during that period as a result of stringent patient selection. Likewise, Fares et al. accomplished a high POD1 discharge rate of up to 94.8% from a consecutive 96 RYGB case series in a small, teaching community hospital with only 5.2% complications [28]. Nevertheless, the study group comprised 55% of patients selected from a total caseload of 173. Lam et al. reported their recent work which yielding remarkable results in terms of 83.1% of patients achieving POD1 discharge with a 1.5% readmission rate whereas they selected 130 out of 240 total cases in their research, and all subjects were receiving SG [29]. Even so, there was no coherent criterion for subject selection and risk stratification among these studies. Although individuals bearing high-risk profiles are consistently deemed unsuitable for enrollment[10, 11, 20], other studies have demonstrated that quality improvement can be attained for some of these vulnerable groups with preserved safety profiles [30]. As a result, our series comprised various susceptible groups; for example, 5 (5.6%) patients were aged > 65 yrs. (range, 65–74 yrs.), 4 (4.4%) patients had a BMI of > 50 kg/m2 (range, 52.5–73.7 kg/m2), and two other patients had a wheelchair-bound status. Notwithstanding, except for a 67-year-old male patient who experienced an abdominal wall hematoma, none of these susceptible patients experienced 30-day complications. Compared to an LOS ranging from 1 day to 2.9 days, readmission rates between 1.7% and 8.1%, early complication rates between 2.8% and 18.3%, and mortality rates of up to 0.7% across former, high-volume studies[12, 24–26, 30], a total LOS of 2.6 days, readmission rate of 1.1% and a total complication rate of 5.5% was accomplished in our series and fall in line with these valuable large studies. Notably, an early hospital discharge (POD1) was possible in 45.6% of our ERAS patients, which is an inferior result if compared with those of the preceding larger series with POD1 discharge rates ranging from 60–84% [24, 26, 30]. Addressing the implementation process, Bamgbade et al. demonstrated that POD1 discharge rates increased from 5–65% over time as their study matured [30]. Barreca et al. also referred a significantly enhanced POD1 discharge rate from 1.6–39.7% after RYGB during a two-year study [31]. Under such circumstances, the overall improvement of the POD1 discharge rate from 1.6–45.6% as the study progressed can be taken as obvious progress and coherent with above studies.
On the other hand, a noticeable tendency toward an increase in adverse outcomes was found in several studies that were specifically endorsed with an unselective approach. For example, Geubbels et al. followed a cohort of 360 unselected RYGB patients and found an increasing early complication rate (from 17.3–18.3%) and an increasing readmission rate (from 4.8–8.1%) after ERAS conduction [32]. Similarly, Mannaerts et al. reported a significantly higher minor complication rate (20.7% vs. 16.1%, P = 0.013) and a higher ER visit rate (16.8% vs. 12.5%, p = 0.015) [33]. Unlike the aforementioned studies, a tendency of decreasing 30-day ER visits (2 (2.2%) vs. 5 (8%)), readmissions (1 (1.1%) vs. 3 (4.8%)), 30-day complication rates (5 (5.5%) vs. 6 (9.7%)), and unplanned procedures or interventions (1 (1.1%) vs. 2 (3.2%)) was found via our ERAS regimen despite none of these values reaching statistical significance. Comparing patients discharged on POD1 with those discharged later, there was no statistically significant increase in ER visits (1/41 (2.4%) vs. 1/49 (2%)), readmissions (1 /41 (2.4%) vs. 0) or overall complication rates (1/41 (2.4%) vs. 4/49 (8.2%)). Therefore, our initial result did not come at the expense of patient safety.
Regarding patients that failed discharge planning, systematic review reported that the most common postoperative reasons were complications such as abdominal pain, nausea, vomiting, bleeding, and atelectasis [19]. Other factors such as preoperative opioid use, history of psychiatric illness, depression/anxiety, OSA, CKD, and CHF served as additional barriers that hindered expeditious discharge [11]. In our series, six patients (6.7%) stayed more than three days (LOS > 3). Except for one patient who experienced GI bleeding that required extending the index LOS to 4 days, none of our patients who failed planned discharge had complications as the cause. Compared to prior larger studies in which 6.4% of subjects ended up with a prolonged LOS [32], the present investigation demonstrated acceptable compliance with the current ERAS program.
It is clear that a major difference in procedures was noted between groups, with significantly more patients who underwent RYGB in the ERAS group. The reason was attributed to the growing concern regarding long-term sequelae, such as anemia and bile reflux after OAGB, as the study progressed [34–36]. Thereafter, we modified our approach to preferably suggesting RYGB for younger patients (< 40 yrs.) and those with gastroesophageal reflux disease or DM despite the lack of established guidelines to support such practice. Apart from this approach, there are likely many factors uncontrolled in a before-and-after study as systemic reviews have generally revealed heterogeneity and methodological bias among many preceding ERAS studies [18]. Since there were no distinctive advantages regarding safety profiles in the comparison of RYGB to OAGB [37] and there were no differences in other demographic features, we believed that comparing results between groups was viable. Our study shows that ERAS can be safely performed unselectively under low-volume setting and provided with beneficial effects usually reported from high-volume, specialized centers.